Superficial Thrombophlebitis (Saphenous Tributary)

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?

Not FDA-cleared for superficial thrombophlebitis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.

Welche Evidenz existiert?

Tier C (investigational). One small uncontrolled case series describes pain reduction; there are no randomized controlled trials. Evidence-based therapy includes oral NSAIDs for pain, fondaparinux 2.5 mg daily for 45 days (or LMWH) for proximal saphenous involvement (CALISTO trial), graduated compression, leg elevation, and warm compresses. Duplex ultrasound is essential to assess thrombus length and rule out deep vein thrombosis or junctional extension — saphenofemoral or saphenopopliteal junction involvement requires anticoagulation.

Hauptrisiken

• Missed or unrecognized DVT propagation (must be ruled out by duplex ultrasound first)
• Bleeding from bite sites for 6 to 24 hours after detachment, magnified by concurrent NSAID use
• Bruising and tenderness over the leg for 5 to 10 days
• Local skin infection or septic thrombophlebitis if infection is present
• Aeromonas infection (uncommon)
• Allergic reaction to leech saliva (uncommon)
• Triggering pulmonary embolism if DVT extension is not recognized
• Delay or replacement of evidence-based fondaparinux when junctional involvement is present

Wer dies nicht in Betracht ziehen sollte

• Patients with deep vein thrombosis (must rule out with duplex ultrasound)
• Patients with saphenofemoral or saphenopopliteal junction involvement (anticoagulation primary)
• Patients with septic thrombophlebitis (antibiotics primary)
• Patients on anticoagulants, with hemophilia, or with severe anemia
• Pregnant patients (require hematology guidance)
• Patients with critical limb ischemia (ABI under 0.4)

Was Sie Ihren Kliniker fragen sollten

• Has a duplex ultrasound been performed to characterize the thrombus and rule out DVT or junctional extension?
• What is the length of the thrombus, and is anticoagulation indicated (e.g. CALISTO criteria)?
• Have I been screened for hypercoagulable conditions if the thrombophlebitis is unprovoked or recurrent?
• Am I a candidate for fondaparinux 2.5 mg daily for 45 days?
• Where exactly will leeches be placed — adjacent to, NOT on, the thrombosed segment?
• What is my plan for graduated compression and follow-up duplex?
• What is the practitioner's experience and Aeromonas-prevention plan?

Wann dringende medizinische Versorgung suchen

• Sudden shortness of breath, chest pain, cough with blood, fainting, or rapid heart rate (possible pulmonary embolism — call 911)
• New unilateral leg swelling, severe pain extending into the deep system, or red warm area (DVT propagation)
• Fever, chills, or severe pain along the vein (septic thrombophlebitis)
• Spreading red streaks up the leg (lymphangitis)
• Bleeding from a bite site lasting more than 24 to 48 hours
• Severe leg pain, coldness, or pallor (acute arterial event)
• Hives, throat tightness, or breathing difficulty